Academic Appointments
- Albert B. and Judith L. Glickman Professor of Neurology at CUMC
Cheryl Waters MD FRCP(C), holds bachelors and masters degrees in Pharmacology from the University of Toronto, where she studied dopamine receptor function with Philip Seeman. She completed medical school at University of Toronto, an internship at University of Chicago, and returned to Toronto for Internal Medicine, Neurology and a fellowship in Clinical Pharmacology. She moved to California and developed the Movement Disorder Program at the University of Southern California. Dr. Waters then moved to New York to take on her current position as Chief of Clinical Practice and Services in the Division of Movement Disorders. She has been involved in research on the genetics of Parkinson's disease and the treatment of this disorder. She has authored numerous articles and book chapters and a book in its seventh edition: Diagnosis and Management of Parkinson's Disease. She has been an investigator in numerous studies involving a variety of new medical and surgical treatments. She is the first to hold the Albert B. and Judith L. Glickman Chair in Neurology.
Departmental Appointments
- Department of Neurology
Division of Movement Disorders
Education and Training
- University of Toronto Faculty of Medicine
- Residency: University of Toronto Hospitals
- Fellowship: University of Toronto Hospitals
Links
NIH Grants
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GZ/SAR402671 IN PATIENTS WITH EARLY-STAGE PARKINSON''S DISEASE CARRYING A GBA MUTATION OR OTHER PRESPECIFIED VARIANT (P&S Industry Clinical Trial)
Jun 1 2017 - Jun 30 2022
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY INVESTGATING THE EFFICACY AND SAFETY OF CVT 301 (LEVODOPA INHALATION POWDER) IN PARKINSON''S DISEASE PATIENTS WITH MOTOR RESPONSE FLUCTUATIONS (OFF PHENOMENA) (P&S Industry Clinical Trial)
Apr 1 2015 - Apr 1 2020
" A PHASE 3, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF ORAL ISTRADEFYLLINE 20 AND 40 MG/DAY AS TREATMENT FOR SUBJECTS WITH MODERATE TO SEVERE PARKINSON''S DISEASE" (P&S Industry Clinical Trial)
Apr 25 2014 - Apr 25 2019
CLINICAL COORDINATION CENTER FOR STEADY-PD3 (Federal Gov)
Aug 1 2014 - Mar 31 2019
PHASE 3 TRIAL OF INOSINE FOR PARKINSON S DISEASE CCC (Federal Gov)
Sep 1 2015 - Jun 30 2017
SETTLE EXT 28850 (P&S Industry Clinical Trial)
Dec 14 2011 - Dec 14 2016
MOTION EXT (P&S Industry Clinical Trial)
Oct 11 2011 - Oct 11 2016
SYN115-CL02 (P&S Industry Clinical Trial)
Jun 28 2011 - Jun 28 2016
A PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED DOSERANGE-FINDING EFFICACY AND SAFETY STUDY OF PRELADENANT IN (P&S Industry Clinical Trial)
Jan 21 2011 - Jan 21 2016
OPEN-LABEL, 12-MONTH SAFETY AND EFFICACY STUDY OF LEVODOPA- CARBIDOPA INTESTINAL GEL IN LEVODOPA-RESPONSIVE PARKINSON"S (P&S Industry Clinical Trial)
Dec 15 2010 - Dec 15 2015
A PHASE III, DOUBLE-BLIND,PLACEBO-CONTROLLED,RANDOMISED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF A DOSE RANGE OF 50 (P&S Industry Clinical Trial)
Nov 11 2010 - Nov 11 2015
AFQ056A2216- (P&S Industry Clinical Trial)
Aug 23 2010 - Aug 23 2015
A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMISED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF A LOW AND HIGH (P&S Industry Clinical Trial)
Jul 29 2010 - Jul 29 2015
OPEN-LABEL CONTINUATION TREATMENT STUDY WITH LEVODOPA INSTESTINAL GEL IN SUBJECTS WITH ADVANCED PARKINSON"S DISEASE AND (P&S Industry Clinical Trial)
Jun 15 2010 - Jun 15 2015
AN OPEN LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX066 IN SUBJECTS WITH PARKINSON"S DISEASE (P&S Industry Clinical Trial)
Sep 8 2010 - Jun 8 2015
A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPX066 IN ADVANCED PARKING''S DISEASE (P&S Industry Clinical Trial)
Nov 16 2009 - Nov 16 2014
A PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPX066 IN SUBJECTS WITH PARKINSON''S DISEASE (P&S Industry Clinical Trial)
May 21 2009 - May 21 2014
SOLVAY -- S187 3 004 (P&S Industry Clinical Trial)
Jun 13 2008 - Jun 30 2012
SCHWARTZ BIOS--SP921 (P&S Industry Clinical Trial)
Dec 4 2007 - Jun 30 2012
A RANDOMOZED,DOUBLE-BLIND,DOUBLE-DUMMY, EFFICACY, SAFETY ANDTOLERABILITY STUDY OF LEVODOPA-CARBIDOPA INTESTINAL GEL IN L (P&S Industry Clinical Trial)
May 1 2009 - May 1 2012
EFFECT OF COENZYME Q10 IN PARKINSONS DISEASE - PHASE 3 (QE3) (Federal Gov)
Dec 1 2007 - Nov 30 2011
A LONGITUDINAL OBSERVATIONAL FOLLOW-UP OF THE PRECEPT STUDY COHORT (POSTCEPT) (Federal Gov)
Jan 1 2007 - May 31 2011
TWO YEAR BLINDED ASSESSMENT OPHTHALMOLOGIC SAFETY STUDY OF PRAMIPEXOLE IR VERSUS ROPINIROLE IN EARLY PARKINSON"S (P&S Industry Clinical Trial)
Jul 8 2005 - Dec 31 2010
EVALUATION OF BLOOD BIOSPECTROSCOPY AS A NOVEL DIAGNOSTIC TE ST FOR IDIOPATHIC PARKINSON DISEASE (PD BIOSPEC) (Private)
Aug 4 2009 - Oct 4 2010
ACUPUNCTURE/MOXIBUSTIONS FOR PEROPHERAL IN PTS WITH HIV (Federal Gov)
Jul 1 2005 - Jun 30 2009
Publications
Espay AJ, Pagan FL, MD,Walter BL, MD; Morgan JC, Elmer LW,. Waters CH,et al. Optimizing extended-release carbidopa/levodopa in Parkinson’s disease: Consensus on conversion from standard therapy. Neurology Clinical Practice 2017;7:1-8
Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB. Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: A lipidomic analysis. PloS one. 2017 Feb 17;12(2):e0172348.
Sklerov, M; Waters, C. Understanding Multiple System Atrophy: Could Genetics Lead the Way? US Neurology, 2016;12(2):110–2.
DOI: https://doi.org/10.17925/USN.2016.12.02.110
Alcalay R.N, Levy OA, Wolf P, Oliva P, Zhang, X.K, Waters,CH, et al. (2016). SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease. npj Parkinson's Disease, 2, 16004.
Alcalay RN, Levy OA, Waters CH et al, Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain Jun 2015, DOI: 10.1093/brain/awv179
Waters CH, Nausieda P, Dzyak L, et al, Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial. CNS Drugs 2015:29:4: 341-350.
Gan-Or Z, Alcalay RN, Bar-Shira A, Leblond C, Postuma RB,Ben-Shachar S, Waters C, et al. Genetic markers of Restless Legs Syndrome in Parkinson Disease. Park Related Disordshttp://dx.doi.org/10.1016/j.parkreldis.2015.03.010
Sharp ME , Caccappolo E , Mejia-Santana H , Tang M –X , Rosado L , Orbe Reilly M , Ruiz D , Louis ED , Comella C, Nance M , Bressman S , Scott WK , Tanner C , Mickel , Waters C et al The relationship between Obsessive-Compulsive symptoms and PARKIN genotype: The CORE-PD study Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065
Waters, Cheryl H: Diagnosis and Management of Parkinson's Disease. Professional Communications Inc., Caddo, Oklahoma. 7th edition, 2014.
Kestenbaum M, Waters C. Magnetic Resonance Imaging and Dopamine Transporter Single Photon Emission Tomography in Parkinson’s Disease—When Should We Use Them? US Neurology,2014;10(2):90–1
Marek K1, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; For The Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study Neurology 2014;82:1791-1797.
Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy OA, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A. Comparison of Parkinson Risk in Ashkenazi Jewish Gaucher Patients and GBA Heterozygotes 2014 Jun;71(6):752-7. doi: 10.1001/jamaneurol.2014.313.
Waters C. The development of the rotigotine transdermal patch: a historical perspective. Neurol Clin. 2013 Aug;31(3 Suppl):S37-50. doi: 10.1016/j.ncl.2013.04.012. Epub 2013 Jun 14.
Arkadir D, Greene PE, Waters CH, Moskowitz CB, Sharp ME. Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathy. Park Relat Disord2013 Aug;19(8):774-5. doi: 10.1016/j.parkreldis.2013.04.016. Epub 2013 May 13.
Alcalay RN, Caccappolo E , Mejia-Santana H , Tang M –X , Rosado L , Orbe Reilly M,Ruiz D , Louis ED , Comella C , Nance M , Bressman S , Scott WK , Tanner C , Mickel S , Waters C et al, Cognitive and motor function in long duration PARKIN PD. Arch Neurol 2013 Nov 4. doi: 10.1001
Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C et al. Parkinson Disease Phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 10/15/2013.
Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa – levodopa (IPX066) compared with immediate – release carbidopa – levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomized, double-blind trial. The Lancet Neurology 2013;12: 346-356.
Liu X, Cheng R, Ye X, Verbitsky M, Kisselev S, Mejia-Santana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford B, Fahn S, Marder K, Lee JH and Clark LN. Increased rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease among Ashkenazi Jews. Molecular Genetics and Genomic Medicine. 2013. 1(3), 142-154.
Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN. Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Counsel 2013. Doi 10.1007/s10897-013-9618-y
Waters C, Smolowitz J: Sexual Dysfunction. In: Parkinson's disease: second edition, CRC press, Pfeiffer R, Wszolek Z, Ebadi M,Eds, 2013, pp 343-352.
Waters CH and Smolowitz J: Impaired Sexual Function. In: Parkinson’s Disease and Nonmotor Dysfunction. Pfeiffer RF, Bodis-Wollner I (eds) Humana Press (Springer Science, New York) 2013, pp 173-187.
Waters C, The Development of the Rotigotine Transdermal Patch: A Historical Perspective Neurologic Clinics 2013 Aug;31(3 Suppl):S37-50. doi: 10.1016/j.ncl.2013.04.012. Epub 2013 Jun 14.
Wright, B Waters CH. Continuous Dopaminergic Delivery to Minimize Motor Complications in Parkinson’s Disease. Expert reviews of Neurotherapeutics2013 Jun;13(6):71929. doi: 10.1586/ern.13.47.
For a complete list of publications, please visit PubMed.gov
